PCI Biotech - Rights Issue - NOK 360 million
PCI Biotech is a cancer focused biopharmaceutical company developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. The PCI technology works by inducing triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities. One bile duct cancer study is currently in clinical development. The company is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination.
We thank PCI Biotech for the vote of confidence and congratulate on the transaction.
Latest news
Arctic Securities - Arctic Securities ramps up its Swedish operations
Arctic Securities ramps up its Swedish operations with new key hires in Stockholm to strengthen its full-service Nordic investment bank offerings. Gustav Rosén will assume the role of CEO Sweden.
Arctic Securities - TÝR Markets and Arctic Securities form a collaboration
TÝR Markets and Arctic Securities form a collaboration providing clients access to selected digital assets in a fast-growing market
Arctic Securities - Strong Attendance and Clear Demand Signals at the Arctic Seafood Conference 2025
Arctic Securities welcomed nearly 400 participants to this year’s Arctic Seafood Investor Conference at Hotel Continental, where global demand dynamics took centre stage.
Arctic Securities - Arctic med flere pallplasser og størst vekst på meglerbordet
Arctic Securities tar ni pallplasser i Kapitals årlige meglerhuskåring, med Norges beste aksjemeglere og størst vekst på meglerbordet.
Arctic Securities - Arctic top-ranked in Prospera 2025
Arctic Securities secured several leading positions in the Prospera Nordic High Yield Investor Survey 2025.
Arctic Securities - Arctic Securities Partners with Børsgruppen Aktie
Arctic Securities is pleased to partner with Børsgruppen Aktie at BI Norwegian Business School.